HC Wainwright Issues Positive Outlook for Rallybio Earnings

Rallybio Co. (NASDAQ:RLYB) – Research analysts at HC Wainwright increased their Q2 2025 EPS estimates for Rallybio in a report issued on Wednesday, April 9th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.23) per share for the quarter, up from their prior estimate of ($0.29). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Rallybio’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Rallybio’s Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.97) EPS.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.15 million.

Separately, Citizens Jmp downgraded Rallybio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $9.33.

Rallybio Stock Performance

Shares of RLYB opened at $0.25 on Friday. The stock has a market capitalization of $10.42 million, a price-to-earnings ratio of -0.16 and a beta of -1.35. Rallybio has a 52 week low of $0.22 and a 52 week high of $2.77. The stock has a fifty day moving average of $0.64 and a 200-day moving average of $0.89.

Hedge Funds Weigh In On Rallybio

A number of hedge funds have recently modified their holdings of the business. Northeast Financial Consultants Inc raised its position in Rallybio by 336.5% during the 4th quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock worth $93,000 after purchasing an additional 74,334 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Rallybio by 11.4% in the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after buying an additional 24,980 shares during the period. Renaissance Technologies LLC raised its position in shares of Rallybio by 9.3% during the fourth quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock worth $424,000 after acquiring an additional 37,618 shares during the last quarter. Allostery Investments LP acquired a new position in shares of Rallybio in the fourth quarter worth approximately $771,000. Finally, Almitas Capital LLC boosted its holdings in Rallybio by 48.3% in the fourth quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock valued at $1,246,000 after acquiring an additional 422,685 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.